CARMAT
Vélizy-villacoublay
About CARMAT
CARMAT is a medtech company that develops and manufactures bioprosthetic artificial hearts for the healthcare industry. The company is offering biocompatible, auto-regulated total artificial hearts, including right and left ventricles designed to be as close as possible to the human heart. It is designed for patients suffering from chronic terminal heart failure reaching class IV on the New York Heart Association classification; or acute terminal heart failure following a massive myocardial infarction. CARMAT’s aim is to offer a reliable new treatment and innovative therapeutic solution to heart failure patients, who are not eligible for a transplant and who have exhausted every drug-related possibility. It was launched in 2008 and is based in Vélizy-villacoublay.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $288.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2025)
- Ticker: epa:ALCAR
- Website: carmatsa.com
- Phone: +33139456450
Industries & Categories
Health Care, Manufacturing, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/carmat-41111 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.